Literature DB >> 11919336

Clinical and biochemical determinants of bone metabolism and bone mass in adolescent female patients with anorexia nervosa.

Laura Audí1, Deisi M Vargas, Miquel Gussinyé, Diego Yeste, Gertrudis Martí, Antonio Carrascosa.   

Abstract

Among pathologies prevalent in western societies, anorexia nervosa has increased over the last decade. Its effects on bone mass need to be defined, and prognostic factors, either clinical or biochemical, could aid clinicians in individual patient management. To determine which clinical and/or biochemical parameters could be related to bone mass status in adolescent female anorexia nervosa patients, 73 female patients were classified according to different stages of their illness and studied in terms of clinical and biochemical parameters and bone densitometric mineral content at lumbar spine. Patients (age 17.2 +/- 1.7 y, mean +/- SD) with Tanner pubertal stage 5, regular menstruation for more than 3 mo before the onset of secondary amenorrhea, and diagnosed with anorexia nervosa were consecutively studied and classified in three clinical situations: I) active phase (34 patients): undernourished and amenorrheic; II) weight recovered but still amenorrheic (20 patients); III) fully recovered (19 patients). Clinical data were recorded at the time of bone density measurement, concomitant with blood sample extraction for study of IGF-I, IGF-binding protein 3 (IGFBP-3), IGFBP-1, estradiol, sex hormone-binding globulin, dehydroepiandrosterone sulfate, prealbumin, amino-terminal propeptide of procollagen III, osteocalcin, bone alkaline phosphatase, carboxy-terminal propeptide of procollagen I, amino-terminal propeptide of procollagen I, carboxy-terminal telopeptide of collagen I, 25-OH-vitamin D, 1,25(OH)(2)-vitamin D, and parathormone. In addition, a 24-h urine collection was made for cortisol, GH, deoxypyridinoline, amino-terminal telopeptide of collagen I, and calcium and creatinine content analysis. IGF-I, estradiol, and biochemical bone formation markers were higher and IGFBP-1, sex hormone-binding globulin, and biochemical bone resorption markers were lower in the weight-recovered stages (stages II and III) compared with the active phase (stage I). Bone formation markers correlated positively with body mass index SD score and IGF-I, whereas bone resorption markers correlated negatively with body mass index SD score and estradiol. Although no statistically significant differences regarding lumbar spine bone mineral density SD score values were recorded among the three stages of the illness, the proportion of osteopenic patients was clearly lower among stage III patients. The actual bone mineral density was inversely related to the duration of amenorrhea and directly related to duration of postmenarcheal menses before amenorrhea. In addition, a subset of osteopenic patients (five of 19) in the fully clinically recovered group with accelerated bone turnover was identified. Normal circulating estrogen level exposure time predicts actual bone mineral density at lumbar spine in young adolescent anorexia nervosa patients. In addition to psychiatric and nutritional interventions, estrogen-deprivation periods must be shortened to less than 20 mo. Patients remaining osteopenic at full clinical recovery require additional follow-up studies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11919336     DOI: 10.1203/00006450-200204000-00016

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  24 in total

1.  Skeletal outcomes by peripheral quantitative computed tomography and dual-energy X-ray absorptiometry in adolescent girls with anorexia nervosa.

Authors:  A D DiVasta; H A Feldman; J M O'Donnell; J Long; M B Leonard; C M Gordon
Journal:  Osteoporos Int       Date:  2016-07-08       Impact factor: 4.507

Review 2.  State of the art systematic review of bone disease in anorexia nervosa.

Authors:  Madhusmita Misra; Neville H Golden; Debra K Katzman
Journal:  Int J Eat Disord       Date:  2015-08-27       Impact factor: 4.861

3.  A 2-year prospective study of bone metabolism and bone mineral density in adolescents with anorexia nervosa.

Authors:  C Mika; K Holtkamp; M Heer; R W Günther; B Herpertz-Dahlmann
Journal:  J Neural Transm (Vienna)       Date:  2007-08-06       Impact factor: 3.575

4.  Hip structural analysis in adolescent boys with anorexia nervosa and controls.

Authors:  Madhusmita Misra; Debra K Katzman; Hannah Clarke; Deirdre Snelgrove; Kathryn Brigham; Karen K Miller; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2013-05-07       Impact factor: 5.958

Review 5.  An overview of the metabolic functions of osteocalcin.

Authors:  Jianwen Wei; Gerard Karsenty
Journal:  Curr Osteoporos Rep       Date:  2015-06       Impact factor: 5.096

6.  Searching for additional endocrine functions of the skeleton: genetic approaches and implications for therapeutics.

Authors:  Jianwen Wei; Stephen Flaherty; Gerard Karsenty
Journal:  Expert Rev Endocrinol Metab       Date:  2015-06-16

7.  Vitamin D status in young Swedish women with anorexia nervosa during intensive weight gain therapy.

Authors:  Anna Svedlund; Cecilia Pettersson; Bojan Tubic; Per Magnusson; Diana Swolin-Eide
Journal:  Eur J Nutr       Date:  2016-06-15       Impact factor: 5.614

Review 8.  Bone metabolism in anorexia nervosa: molecular pathways and current treatment modalities.

Authors:  D J Howgate; S M Graham; A Leonidou; N Korres; E Tsiridis; E Tsapakis
Journal:  Osteoporos Int       Date:  2012-08-09       Impact factor: 4.507

9.  Anorexia nervosa, osteoporosis and circulating leptin: the missing link.

Authors:  I Legroux-Gérot; J Vignau; E Biver; P Pigny; F Collier; X Marchandise; B Duquesnoy; B Cortet
Journal:  Osteoporos Int       Date:  2010-01-06       Impact factor: 4.507

10.  Age-related differences in hormonal and nutritional impact on lean anorexia nervosa bone turnover uncoupling.

Authors:  B Galusca; C Bossu; N Germain; M Kadem; D Frere; M H Lafage-Proust; F Lang; B Estour
Journal:  Osteoporos Int       Date:  2006-03-16       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.